Subtle cognitive impairments in memory, attention, and executive functioning in patients with post-COVID syndrome and their relationships with clinical variables and subjective complaints

Kozik, V.^{a,*}, Reuken, P.^b, Utech, I.^a, Gramlich, J.^b, Stallmach, Z.^b, Demeyere, N.^c, Rakers, F.^a, Schwab, M.^a, Stallmach, A.^{b,d,+}, Finke, K.^{a,e,+}

^a Department of Neurology, Jena University Hospital/Friedrich-Schiller-University Jena, Am Klinikum 1, 07743 Jena, Germany

^b Department of Internal Medicine IV (Gastroenterology, Hepatology and Infectious Diseases), Jena University

10 Hospital/Friedrich-Schiller-University Jena, Am Klinikum 1, 07743 Jena, Germany

^c Department of Experimental Psychology, University of Oxford, Radcliffe Observatory Quarter, Oxford OX2
 6GG, UK

^d Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany

^e Department of Psychology, Ludwig-Maximilians-Universität München

15

5

* corresponding author

⁺ shared senior authorship

Words: 3,048

20

Abstract

Background and objectives. Cognitive symptoms persisting beyond three months following COVID-19 present a considerable disease burden. We aimed to establish a domain-specific cognitive profile of post-COVID syndrome (PCS) and relationships with subjective cognitive complaints and clinical

25 variables to provide relevant information for the understanding of cognitive dysfunction and its

predictors in a clinical cohort with PCS.

Methods. In this cross-sectional study, we compared cognitive performance on the clinically viable Oxford Cognitive Screen-Plus between a large post-COVID cohort (n = 282) and a sociodemographically matched healthy control group (n = 52). We assessed group differences in terms of

30 fatigue and depression as well as relationships between cognitive dysfunction and clinical and patientreported outcomes.

Results. On a group-level, patients scored significantly lower on delayed verbal memory (nonparametric effect size r = .13), attention (r = .1), and executive functioning (r=.1) than healthy controls. In each of these domains, 10-20% of patients performed more than 1.5 SD below the healthy

control mean. Delayed Memory was particularly affected and a small proportion of its variance was explained by hospitalisation ($\beta = -.72$, p < .01) and age ($\beta = -.03$, p < .05; R²adj. = .08). Attention scores were significantly predicted by hospitalisation ($\beta = -.78$, p < .01) and fatigue ($\beta = -.04$, p < .05; R²adj. = .06).

Discussion. PCS is associated with long-term cognitive dysfunction, particularly in delayed verbal memory, attention, and executive functioning. Deficits in delayed memory performance seem to be of particular relevance to patients' subjective experience of impairment. Initial disease severity, current level of fatigue, and age seem to predict cognitive performance, while time since infection, depression, and pre-existing conditions do not. Longitudinal data are needed to map long-term course of cognitive dysfunction in PCS.

45 1 Introduction

65

A considerable number of individuals affected by coronavirus disease 2019 (COVID-19), including mild and asymptomatic cases, report long-term cognitive effects, in addition to fatigue and physical symptoms (e.g., ¹⁻⁵; for reviews see ^{6,7}). If symptoms develop during or after infection, persist for more than 12 weeks and cannot be explained by another diagnosis, the patient suffers from post-COVID-19

- 50 syndrome (PCS), according to NICE guidelines⁸. A recent study with 355 patients from a post-COVID outpatient clinic^a, reported that over 90% reported signs of fatigue and depression and 23% performed below cut-off in a cognitive screening (Montreal Cognitive Assessment; MoCA⁹). Similar incidences of below cut-off MoCA scores were reported following SARS-CoV-2 infection in a recent population-based study¹⁰.
- Long-term cognitive deficits are of high clinical relevance, as they have a strong impact on patients' daily functioning, employment, and the ability to return to work, and thus, constitute a large disease burden¹¹. A characterisation of the cognitive profile in PCS and the relationships of deficits in different domains with subjective cognitive complaints and relevant clinical variables is of the essence, as it could foster the understanding of the underlying pathogenic mechanisms and improve knowledge of
- 60 the course of the syndrome. However, the overall cut-offs for short cognitive screens are not suitable for such analyses.

Initial evidence from studies using more comprehensive test batteries point towards deficits in the domains of attention, memory, and executive functioning following SARS-CoV-2 infection (e.g., ¹²⁻¹⁵, for review see ¹⁶). However, in these studies, samples were either small or assessed remotely in uncontrolled settings, participants did not consistently meet criteria for the diagnosis of initial infection or PCS⁸, and/or healthy control groups were missing.

For the reliable identification of a domain-specific neuropsychological profile and the clinical factors influencing the domains, it is crucial to assess large, well-defined patient groups with appropriate assessment tools. Furthermore, comparisons with matched, healthy groups are needed to control for

⁷⁰ the potential influence of generally increased psychological stress under conditions of a pandemic on ^a The present study's patient sample was recruited from the same outpatient clinic, but using different inclusion criteria (see Methods).

cognitive functions. However, the use of comprehensive neuropsychological batteries, particularly in a standardised, in-person setting is not easily scalable, as it is time-consuming regarding application, scoring, and interpretation, and requires specialised staff.

The present study used a clinically suitable, time- and cost-effective alternative to meet these
challenges. The Oxford Cognitive Screen-Plus^b (OCS-Plus¹⁷) is a tablet-based screening tool, which
bridges the gap between short-from screens and comprehensive neuropsychological batteries, in terms
of resource-efficiency and its psychometric properties. It facilitates a more detailed screening of
domain-specific cognitive functions and the establishment of a profile of spared and affected domains
in subclinical and clinical populations^{17,18}. Its use requires little training from operating staff and
outcome measures are scored automatically.

Using this innovative test, the first aim of this study was to elucidate the cognitive profile associated with PCS by assessing all potentially relevant domains with a large, clinical sample in comparison to a healthy control group, matched by age, sex, and education. The second aim was to establish relationships between affected cognitive domains and subjective cognitive complaints, as well as relevant clinical variables, such as initial disease severity, time since infection, age, depression,

fatigue, and comorbidities in order to identify predictors of specific cognitive deficits in this clinically referred, well-defined post-COVID cohort.

2 Methods

85

2.1 Participants

- A total of 282 patients and 52 healthy controls were included in this study. We included all patients who presented to the post-COVID outpatient clinic at Jena University Hospital (Germany) between August 2020 and March 2022 and who had previously been confirmed positive for SARS-CoV-2 using a PCR-test, were willing and able to give informed consent, and were capable of taking part in the assessment. We further only included participants in either group, who did not have a history of
- 95 relevant neurological or severe psychiatric disorders potentially impairing cognition, substance use

^bWhile the original OCS is a stroke-specific paper-and-pencil bedside screening test, the OCS-Plus is a computerised elaboration of this tool, with broader clinical and subclinical application.

disorder, or relevant vision and hearing problems, and who were between the ages of 18 and 65. We chose the upper age limit to avoid any issues pertaining to cognitive changes due to age-associated neurodegenerative processes. Of 399 patients, who initially presented to the clinic within the given time period, met inclusion criteria and consented to their participation, data for 76 patients is not

- 100 available due to either technical difficulties before or during testing, data for 39 patients is unavailable due to logistical issues or constraints in the clinical setting, and two participants withdrew consent after testing. For a patient-only regression analysis with six predictor variables, we have 80% power to detect effects larger than $R^2 = .05$ with our smallest sub-sample (alpha = .05). Based on the fact of relatively low variability and near ceiling performance on the relevant domain scores of the OCS-Plus
- 105 by healthy, largely elderly participants (see table 8 in ¹⁷), we expect our smaller, but sociodemographically matched control group to strike the balance between sufficiency to represent healthy variability and resource efficiency.

2.2 Assessment

Patients underwent structured anamnesis including the patient's medical history, basic sociodemographic data, and subjective cognitive complaints. All participants completed the depression module of the Patient Health Questionnaire (PHQ-9¹⁹), the Fatigue Assessment Scale (FAS²⁰) and the Brief Fatigue Inventory (BFI²¹). In the same session, cognitive functioning was assessed by research staff using the Oxford Cognitive Screen-Plus¹⁷, which consists of 9^c subtasks: Picture Naming, Semantics, Orientation, Word Memory Encoding, Delayed Recall, Trails, Episodic Recognition,
Figure Copy, and Cancellation (see ¹⁷ and table 1).

Task	Description	Score range
Picture Naming	Participants name four images of low-frequency objects.	0-4
Semantics	Out of an array of four images, participants identify the correct object based on semantic category.	0-4

Table 1:	OCS-Plus	tasks	descriptions
----------	-----------------	-------	--------------

⁵ ^c Due to time constraints in the clinical setting, the OCS-Plus subtask "rule finding" was skipped. Accordingly, scoring for executive functioning differs from the method proposed by Demeyere et al. (2021).

Orientation	Orientation in time and space is assed using four questions pertaining to the current date, location, and the current German chancellor.	0-4
Word Memory Encoding	Participants are tasked with remembering a list of five words, which is presented twice. After each presentation, participants are asked to recall the words (Encoding 1 and Encoding 2).	0 – 5, for Encoding 1 and Encoding 2, each
Trails	In two baseline conditions, participants connect circles and squares in increasing and decreasing order of size, respectively. From this, the Processing Speed score is calculated as baseline time divided by baseline accuracy.	∞
	The switching condition entails connecting circles and squares in a complex, alternating rule, with circles going up and squares going down in size. The Trails Executive Score is calculated as accuracy in the switching condition divided by accuracy in the baseline condition.	0 – 100
Delayed Recall	After the Trails task, participants are asked to recall the encoded words (Delayed Recall).	0-5
	Words, which were not correctly recalled, are presented as part of a multiple-choice array (Delayed Recall and Recognition).	0 – 5
Episodic Recognition	Participants select stimuli (objects or words), which were part of previous tasks out of a multiple-choice array.	0-4
Figure Copy	Participants copy a complex figure consisting of 20 geometric elements, each being scored for presence, position, and accuracy.	0 – 60
	Participants are briefly presented with the same figure again, which then has to be drawn from memory.	0 - 60

Cancellation	Participants are presented with a search array of 60 pictograms	0-30
	of fruit (targets) and vegetables (distractors). Each of the 30	(accuracy) and
		$0 - \infty$ (false
	targets needs to be selected once and in the visible condition,	positive
	selected elements are visibly marked.	selections)
	In the invisible condition, the pictograms are re-arranged and	0-30
	presented again Again each target needs to be selected once	(accuracy) and
	F	$0 - \infty$ (correct
	but in the invisible condition, the markings disappear	revisits)
	immediately after selection.	

Assessment takes approximately 25 minutes and is completed using a stylus pen on a tablet computer. From the OCS-Plus subtasks, six domain scores may be calculated: Naming and Semantic Understanding (Picture Naming + Semantics), Memory Encoding (Encoding 1 + Encoding 2), Delayed Memory (Delayed Recall + Delayed Recall and Recognition), Praxis (Figure Copy + Figure Recall), Attention (Cancellation + Invisible Cancellation), and Executive Functioning (Trails Executive Score – Cancellation false positives¹⁷).

2.3 Statistical Analysis

120

We compared socio-demographic variables between patients and healthy controls using t-tests with

Welch correction to account for the difference in sample sizes and a chi-squared test with Yates' continuity correction to compare sex ratios. Fatigue and depression scores were compared between groups using Welch two sample t-tests. Performance on the OCS-Plus subtasks and overall domain scales was compared between patients and controls using Wilcoxon rank sum tests with continuity correction. Based on the current state of the literature, we selected subtasks and overall domain scores as particularly relevant to our analyses, which capture the domains of attention, memory, and executive functioning. As we expected patients to perform worse in these domains, we used one-tailed tests (alpha = .05). We then examined how many patients fell below a cut-off of 1.5 standard deviations below the healthy sample means on the domains of interest. To take into account the

heterogeneity of symptoms and particularly of cognitive complaints, we split patients into two groups:

- those who complain of both memory and concentration problems (high complainers) and those who report only one or none of these symptoms (low complainers). These groups were then compared in terms of their cognitive performance on the domain scales of the OCS-Plus. To explore predictors of attentional, memory, and executive functioning problems as part of post-COVID syndrome, we performed multiple linear regression analyses within the patient cohort. We included initial disease
- severity, age, days since infection, fatigue, and relevant comorbidities as predictors of performance on the OCS-Plus. The need for hospitalisation i.e., outpatient versus inpatients treatment, was used as a proxy for initial disease severity. Comorbidities were included as an index of five binarised pre-existing conditions: hypertension, coronary heart disease, chronic heart failure, diabetes mellitus, and psychiatric disorders (range: 0 5). To estimate generalisability of the models, we computed
 nonparametric bootstrap (2,000 replications) confidence intervals around coefficients. We then separated patients into two groups for each pre-existing condition, i.e., condition "present" and "not
- present", and compared groups on each cognitive domain to assess the effect of the individual conditions. We corrected for multiple comparisons using the Benjamini-Hochberg procedure (Q = 5%). For each OCS-Plus score, an average 0.12% of data points are missing due to technical difficulties. Analysis was performed using R version 4.2.0²².

2.4 Standard Protocol Approvals, Registrations, and Patient Consents

Written informed consent was obtained from all participants. The study was approved by the ethics committee of the Jena University Hospital [amendment to 5082-02/17].

2.5 Data Availability

155 Anonymised data not published in this article will be made available upon reasonable request.

3 Results

3.1 Sociodemographic and clinical description of post-COVID-19 patients and healthy controls

Basic socio-demographic information for both groups are presented in table 2. There were no differences between groups in terms of age (t = -.76, p = .451), education (t = 1.72, p = .09), or sex

160 ratios (chi-squared = .61, p = .435). Please refer to table 3 for an overview of patient clinical data stratified by hospitalisation.

	Controls (n = 52)	Patients (n = 282)	Total (N = 334)	
Age				
Mean (SD)	45.62 (10.15)	46.80 (11.27)	46.61 (11.15)	
Range	22.00 - 65.00	18.00 - 65.00	18.00 - 65.00	
Sex				
Female	31 (59.6%)	186 (66.0%)	217 (65.0%)	
Male	21 (40.4%)	96 (34.0%)	117 (35.0%)	
Education (years)				
Missing (n)	0	28	28	
Mean (SD)	15.28 (1.97)	14.76 (2.07)	14.85 (2.06)	
Range	11.00 - 18.00	10.00 - 18.00	10.00 - 18.00	

Table 2: Socio-demographic distribution by group

Note. SD = standard deviation

Table 3: Clinical data stratified by need for hospitalisation

Clinical Varia	ıble	Distribution	Missingness		
Weeks since in	nfection, M(SD, Range)	37.3 (17.6, 12 – 104)	0		
Outpatient tr	eatment, n(%)	215 (76.2)	0		
WHO	severity grade, n(%)		1		
	1	3 (1.4)			
	2	210 (98.1)			
	3	1 (0.5)			
Comorbidities			0		
	Cardiovascular diseases, n(%)	60 (27.9)			
	Diabetes mellitus, n(%)	4 (1.9)			
	Psychiatric comorbidities, n(%)	29 (13.5)			
Inpatient treatment, n(%)		67 (23.8)	0		
Hospit	al stay (days), M(SD)	12 (8.8)	0		
Oxyge	n support, n(%)	48 (71.6)	0		

ICU ad	mission, n(%)	22 (33.3)	1
	ICU stay (days), M(SD)	3.2 (7.8)	4
WHO s	severity grade, n(%)		0
	2	4 (6.3)	
	3	11 (16.4)	
	4	26 (38.8)	
	5	20 (29.9)	
	7	6 (9.0)	
Comorbidities			0
	Cardiovascular diseases, n(%)	43 (64.2)	
	Diabetes mellitus, n(%)	10 (14.9)	
	Psychiatric comorbidities, n(%)	11 (16.4)	

Note. M = mean; SD = standard deviation; WHO = World Health Organization; ICU = intensive care unit; cardiovascular diseases included hypertension, coronary heart disease, and chronic heart failure

165

3.2 Subjective cognitive complains, depression, and fatigue

During the anamnestic interview, 69.9% of patients complained of attention and 58.9% of memory problems. 55.7% of patients complained of both attention and memory problems. As the two fatigue questionnaires were highly correlated (r(329) = .78, p < .0001), only the results from the FAS will be

170 used for further analysis. Patients scored significantly higher on the FAS (r = .50, p < .0001) and on the PHQ-9 (r = .44, p < .0001) than controls (see table 4 for complete results).

Table 4: Questionnaire data for controls and patients

		Co	ntrols			Pat	tients		Wilcoxon rank sum test		
Questionnaire	n	Mean	SD	SEM	n	Mean	SD	SEM	W	r ^a	
FAS	50	17.30	4.81	0.68	282	31.27	9.05	0.54	1360	0.50***	
PHQ-9	50	3.92	2.93	0.41	282	10.69	5.57	0.33	2004.5	0.44***	

Note. FAS = Fatigue Assessment Scale; PHQ-9 = Patient Health Questionnaire; SD = standard deviation; SEM = standard error of the mean; r = effect size; ** p<.01; *** p<.001

175

180

3.3 Comparison between patients and healthy controls on OCS-Plus subtasks

Patients scored lower than healthy controls on the tasks Encoding 2 (r = .1, p = .034), Delayed Recall accuracy (r = .12, p = .013), Figure Copy accuracy (r = .1, p = .037), Cancellation false positives (r = .12, p = .013), Figure Copy accuracy (r = .1, p = .037), Cancellation false positives (r = .12, p = .013), Figure Copy accuracy (r = .1, p = .037), Cancellation false positives (r = .12, p = .013), Figure Copy accuracy (r = .1, p = .037), Cancellation false positives (r = .12, p = .013), Figure Copy accuracy (r = .1, p = .037), Cancellation false positives (r = .12, p = .013), Figure Copy accuracy (r = .1, p = .037), Cancellation false positives (r = .12, p = .013), Figure Copy accuracy (r = .1, p = .037), Cancellation false positives (r = .12, p = .013), Figure Copy accuracy (r = .1, p = .037), Cancellation false positives (r = .12, p = .013), Figure Copy accuracy (r = .1, p = .037), Cancellation false positives (r = .12, p = .013), Figure Copy accuracy (r = .12, p = .013), Figure Copy accu -.1, p = .03), and Invisible Cancellation accuracy (r = .12, p = .018). However, none of the comparisons survived correction. Please refer to table 5 for full results.

3.4 Comparison between patients and healthy controls on OCS-Plus domain scales

Patients scored significantly lower than healthy controls on the scales of Delayed Memory (r = .13, p < .01), Executive Functioning (r = .1, p = .033), and Attention (r = .1, p = .027). See table 6 and figure 1 for results stratified by group.

185 Table 5: Performance on the OCS-Plus subtasks per group

	Controls			Patients					Wilcoxon rank sum test				
OCS-Plus task	n	Mean	Median	SD	SEM	n	Mean	Median	SD	SEM	W	р	r
Picture Naming accuracy	52	3.96	4.00	0.19	0.03	280	3.95	4.00	0.26	0.02	7340	0.397	
Semantics accuracy	51	3.92	4.00	0.27	0.04	282	3.89	4.00	0.33	0.02	7419.5	0.249	
Orientation accuracy	52	3.90	4.00	0.30	0.04	282	3.96	4.00	0.19	0.01	6913	0.962	
Encoding 1	52	4.54	5.00	0.64	0.09	274	4.52	5.00	0.66	0.04	7158.5	0.475	
Encoding 2	52	5.00	5.00	0.00	0.00	279	4.94	5.00	0.24	0.01	7696	0.034	0.1*
Delayed Recall accuracy	50	3.78	4.00	1.13	0.16	279	3.24	3.00	1.48	0.09	8327	0.013	0.12*
Delayed Recall and Recognition	51	4.88	5.00	0.33	0.05	279	4.74	5.00	0.56	0.03	7818	0.052	
Episodic Recognition accuracy	51	3.57	4.00	0.57	0.08	280	3.42	4.00	0.72	0.04	7768	0.13	
Trails Executive Score	51	88.54	100.00	16.30	2.28	278	82.03	92.86	24.31	1.46	7918	0.078	
Processing Speed	51	16.62	14.64	7.06	0.99	278	15.03	13.39	6.91	0.41	8094	0.054	
Figure Copy accuracy	43	56.98	58.00	2.88	0.44	279	56.39	57.00	2.85	0.17	7002.5	0.037	0.1*
Figure Recall accuracy	42	47.12	47.50	7.98	1.23	279	46.53	48.00	8.43	0.50	6022	0.386	
Cancellation accuracy	51	29.80	30.00	0.45	0.06	275	29.77	30.00	0.52	0.03	7162	0.363	
Cancellation false positives	51	0.04	0.00	0.20	0.03	276	0.16	0.00	0.44	0.03	6390	0.03	-0.1*
Invisible Cancellation accuracy	51	29.02	29.00	0.97	0.14	275	28.45	29.00	1.55	0.09	8267	0.018	0.12*
Invisible Cancellation correct revisits	52	1.08	0.50	1.38	0.19	276	1.43	1.00	1.91	0.11	6570	0.155	

Note. OCS-Plus = Oxford Cognitive Screen-Plus; SD = standard deviation; SEM = standard error of the mean; r = effect size; * = significant before FDR-correction, ** = significant after FDR-correction; italicised: subtasks of interest

Table 6: Performance on the OCS-Plus domain scales per group

Controls				Patients					Wilcoxon rank sum test				
OCS-Plus scale	n	Mean	Median	SD	SEM	n	Mean	Median	SD	SEM	W	р	r
Naming and Semantic Understanding	51	7.88	8	0.38	0.05	280	7.83	8	0.44	0.03	7478	0.185	
Memory Encoding	52	9.54	10	0.64	0.09	271	9.46	10	0.75	0.05	7296	0.322	
Delayed Memory	50	8.68	9	1.24	0.17	279	7.98	8	1.77	0.11	8438.5	< 0.01	0.13**
Praxis	43	103.86	105	8.92	1.36	279	102.92	105	9.63	0.58	6189	0.369	
Executive Functioning	50	88.7	100	16.46	2.33	275	81.59	92.86	24.79	1.49	7945	0.033	0.1**
Attention	50	58.82	59	1.06	0.15	275	58.22	59	1.72	0.10	8021	0.027	0.1**

Note. OCS-Plus = Oxford Cognitive Screen-Plus; SD = standard deviation; SEM = standard error of the mean; r = effect size; * = significant before FDR-correction, ** = significant after FDR-correction; italicised: domain scales of interest

190



Figure 1: Performance on the OCS-Plus domain scales by controls and patients with post-COVID syndrome

Note. Distribution of scores on the OCS-Plus domain scales of Delayed Memory, Attention, and Executive Functioning, per group. Grey dots represent individual
participants, white squares represent group mean, and dashed lines represent cut-off (1.5 standard deviations below control mean).

3.5 Proportional impairment per group on OCS-Plus domain scales

10.7% of patients scored below the cut-off on Memory Encoding (versus 3.85% of controls), 21.15% of patients scored below the cut-off on Delayed Memory (versus 6% of controls), 19.27% of patients scored below the cut-off on Executive Functioning (versus 8% of controls), and 14.91% of patients
200 scored below the cut-off on Attention (versus 2% of controls; see figure 2, panel A). Out of those patients for whom there is complete data for all domain scores, 53.7% of patients were impaired on at least one domain score (versus 25% of controls), 18.68% scored below the cut-off on at least 2 domains (versus 5% of controls), and 3.89% scored below the cut-off on at least 3 domains (versus 0% of controls; see figure 2, panel B).





Note. Panel A) Percentage of participants under the cut-off (1.5 standard deviations below control mean) per group in the domain scores of interest. Panel B) Percentage of participants per group, who fall under the cut-off in no, one, two, or at least three domain scores.

210 3.6 Relationship between subjective cognitive complaints and Delayed Memory performance

76 patients reported no or only one cognitive symptom and 206 patients reported both attention and memory difficulties. Performance in the Delayed Memory domain differed between those with and those without subjective cognitive complaints (W = 8669, p = .024). There were no performance differences on any other domain scale (see table S1 in the supplemental material for complete results).

215 3.7 Relationships between clinical variables and performance on the domains of Delayed Memory, Attention, and Executive Functioning

The overall model to predict Delayed Memory performance, with hospitalisation, age, days since infection, fatigue, and comorbidities as predictors was significant (F(6, 272) = 4.84, p < .001, R²adj.= .08). Hospitalisation (β = -.72, p < .01) and age (β = -.03, p < .05) significantly predicted Delayed Memory performance. The model to predict performance on the Attention domain score was

also significant (F(6, 268) = 4.07, p < .001, R²adj.= .06), with hospitalisation ($\beta = -.78$, p < .01) and fatigue ($\beta = -.04$, p < .05) as significant predictors. The model to predict performance in the Executive Functioning domain was not significant. Please see table 7 for full results.

220

Table 7: Coefficient-level estimates for models fitted to estimate variation in (1) Delayed Memory, (2) Attention, and (3) Executive Functioning performance

	(1) Delayed Memory	(2) Attention	(3) Executive Functioning
	OLS	OLS	OLS
Intercept	9.564***	59.748***	81.631***
	(8.383, 10.789)	(58.576, 60.844)	(59.821, 99.055)
Hospitalisation	-0.724**	-0.779**	-2.314
(inpatient)	(-1.205, -0.265)	(-1.402, -0.239)	(-10.856, 5.074)
Age	-0.025*	-0.014	0.069

	(-0.042, -0.005)	(-0.032, 0.003)	(-0.200, 0.394)
Days since	0.002*	0.001	-0.025*
infection	(0.000, 0.003)	(0.000, 0.003)	(-0.049, -0.004)
FAS	-0.018	-0.043*	0.184
	(-0.052, 0.013)	(-0.075, -0.012)	(-0.357, 0.676)
PHQ-9	-0.009	0.035	-0.029
	(-0.060, 0.042)	(-0.011, 0.086)	(-0.722, 0.767)
Comorbidities	-0.031	-0.055	-2.505
	(-0.321, 0.239)	(-0.340, 0.232)	(-6.728, 1.762)
Observations	279	275	275
R^2	0.096	0.083	0.027
Adjusted R ²	0.076	0.063	0.005
Residual Std. Error	1.702 (df = 272)	1.668 (df = 268)	24.727 (df = 268)
F Statistic	4.838^{***} (df = 6; 272)	4.067^{***} (df = 6; 268)	1.223 (df = 6; 268)

Note: Coefficients and confidence intervals (nonparametric bootstrap, 2,000 replications, in parentheses), bolded: significant estimates, with bootstrap confidence intervals not overlapping zero; p<0.05; p<0.01; p<0.01; p<0.01

225 On the level of individual comorbidities, those with hypertension performed worse in the Delayed Memory domain. No other comparisons between groups with and without individual comorbidities survived correction. Regression analysis revealed no effect of hypertension on Delayed Memory performance, when controlling for our set of covariates (see S2-S4 in the supplemental material).

4 Discussion

230 In this study, subtle^d, but meaningful impairments in attention, delayed memory, and executive functions as well as preserved basic orientation, language, and visuo-spatial functions were identified in patients with post-COVID syndrome (PCS). High levels of patients' subjective cognitive complaints were associated with poorer performance on the delayed memory scale, but not other ^d Effect sizes ranged from .1–.13, which may be classified as small effects^{23,24}

cognitive domains. In regression analyses we found significant clinical predictors of memory and

- 235 attentional performance, but none for executive functions. Specifically, we found that initial disease severity predicted performance in the domains of attention and delayed recall, in the sense that hospitalised patients performed significantly worse than non-hospitalised patients. Further, older age predicted worse performance on the delayed memory domain and higher levels of fatigue predicted worse performance on the domain of attention. We found no associations between delayed memory or
- 240 attentional performance and time passed since infection, depression, or comorbidities.

The identified neuropsychological profile of patients with PCS fits with results of early studies (e.g., ¹²⁻¹⁴). However, the present study goes beyond these prior studies by documenting persisting deficits in a large patient sample with previous SARS-CoV-2 infection confirmed by laboratory testing and fulfilling the NICE criterion of symptom persistence beyond 12 weeks post-infection⁸ in comparison

to a socio-demographically matched control group. Moreover, our participants were assessed in a faceto-face setting, i.e., under more controllable, standardised conditions than the remote testing used in a large, population-based study (e.g., ¹⁴).

In each of the affected domains — delayed memory, attention, and executive functioning — between 10 and 20% of patients fell below a cut-off of 1.5 standard deviations based on the healthy group

- 250 distribution. In fact, a substantial number of patients showed domain-level deficits, as more than half of patients scored below the cut-off in at least one major domain score and just under a fifth of patients were impaired on multiple domains. Deficits were found most commonly in the delayed verbal memory domain. This is in line with the finding of predominant left-sided parahippocampal gyrus atrophy in individuals affected by SARS-CoV-2^{25,26}. Interestingly, patients who reported high levels of
- 255 subjective cognitive complaints exhibited worse performance in the delayed memory domain. As we found no relations between other domains and subjective cognitive complaints, memory deficits may play a unique role in patients' experience of daily life impairment. We further found relatively high incidences of deficits in attention and executive functioning, which are among the most commonly reported findings in PCS (e.g., ¹²⁻¹⁴).

260 The use of a large patient sample furthermore allowed for analysing the potential influence of relevant clinical variables on cognitive deficits in patients with PCS. In detail, we tested for the influence of the need for hospitalisation during acute infection, time since infection, relevant comorbidities, and age. Additionally, we tested for the influence of current symptoms of fatigue and depression, which, in line with previous studies (e.g., ¹², for review see ²⁷) were heightened in patients compared to healthy 265 controls.

The analyses revealed, firstly, a — relatively small — negative influence of hospitalisation on memory and attention performance. While reports regarding the effect of disease severity on cognitive functioning in heterogeneous samples of participants following SARS-CoV-2 infection are inconsistent (e.g., ¹²⁻¹⁴), this finding contributes to the understanding of this association with memory and attention in PCS. Secondly, and in accordance with the well-established decline in verbal memory performance with increasing age (for meta-analysis see ²⁸), our regression analyses revealed a small influence of age on delayed verbal memory performance. Thirdly, fatigue was a predictor of attention performance, which appears to fit within the context of reduced levels of overall brain arousal and cognitive performance, particularly in the domain of attention (^{29,30}, for review see ³¹). As our analyses revealed no associations between cognitive performance and time since infection they suggest that

275 revealed no associations between cognitive performance and time since infection they suggest that cognitive deficits in the PCS stage may be chronic and no longer improve over time. However, follow-up assessment should provide more conclusive data regarding the long-term course of domain-specific cognitive functioning. Furthermore, as neither depression nor comorbidities were found to be significant predictors, cognitive dysfunctions seem to be due to the infection itself rather than to 280 increased psychological or general health burden.

This study has certain strengths and limitations. Strengths include a large, well-defined post-COVID patient cohort, a socio-demographically matched control group, and the use of an innovative, clinically useful tablet-based assessment tool, which combines resource-efficiency and good psychometric properties. While we did not have access to cognitive performance prior to infection, we mitigated this limitation by including an age- and education-matched control group, as well as by excluding patients with known relevant neurological or psychiatric disorders. Our study was potentially prone to

selection bias, as only patients with severe enough symptoms to report to a specialised clinic were

285

included. However, this study thus provides a valuable insight into the clinical cohort, for which the health care system needs to be prepared, as numbers of COVID-19 survivors, who continue to experience long-term symptoms, are rising.

290

This study identified subtle long-term deficits in attention, memory, and executive functioning persisting for more than three months in patients with PCS. Given the relevance of cognitive deficits for successful reintegration into work and family life, for clinical practice, this indicates a pressing need for the numerous patients suffering from PCS to undergo comprehensive, but time- and cost-

- 295 efficient cognitive screening, using a tool such as the OCS-Plus, which delivers specific domainspecific information not available from shorter screens. This initial assessment can enable clinicians to decide about further diagnostic and treatment steps, such as the necessity to undergo more in-depth neuropsychological and neurological assessment in specialised centres, or to start treatment with cognitive interventions, such as occupational therapy or computerised training targeting affected
- 300 domains. From a research perspective, our cross-sectional approach should be complemented by a longitudinal one, i.e., by testing the same patients again in a large-scale follow-up observation.

Funding

The post-COVID Centre was supported by the Thüringer Aufbaubank (2021 FGI 0060). This work was further supported by funds to KF from the German Forschungsgemeinschaft [DFG, FI 1424/2-1]
and the Horizon 2020 Framework Programme of the European Union (ITN SmartAge, identifier H2020-MSCA-ITN-2019-859890).

Conflict of interest

All authors report no conflict of interest regarding the content of the manuscript.

310

Author contributions

VK: Writing – original draft, data curation, formal analysis, data collection. PR: Conceptualisation & implementation, writing – critical review. IU: Data collection. JU: Data collection. ZS: Data collection. ND: Methodology. FR: critical review. MS: critical review.

315 AS: Conceptualisation, supervision, resources, writing – critical review. KF: Conceptualization, supervision, resources, writing – critical review and editing

Acknowledgments

We would like to thank Claudia Eilert, a representative for the patient support group Long-

320 *COVID Germany* for her expertise and her contributions to the early phases of a project to develop further these mobile cognitive assessment procedures. Additionally, we would like to thank our student assistants Lara Gutfleisch and Antonia Haddenhorst for their contributions to data collection.

325 References

- Boesl F, Audebert H, Endres M, Prüss H, Franke C. A Neurological Outpatient Clinic for Patients With Post-COVID-19 Syndrome — A Report on the Clinical Presentations of the First 100 Patients. Brief Research Report. *Frontiers in Neurology*. 2021-September-16 2021;12doi:10.3389/fneur.2021.738405
- Guo P, Benito Ballesteros A, Yeung SP, et al. COVCOG 1: Factors Predicting Physical, Neurological and Cognitive Symptoms in Long COVID in a Community Sample. A First Publication From the COVID and Cognition Study. Original Research. *Frontiers in Aging Neuroscience*. 2022-March-17 2022;14doi:10.3389/fnagi.2022.804922
- Lund LC, Hallas J, Nielsen H, et al. Post-acute effects of SARS-CoV-2 infection in
 individuals not requiring hospital admission: a Danish population-based cohort study. *The Lancet Infectious Diseases*. 2021;21(10):1373-1382.
 - Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nature Medicine*.
 2021/04/01 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z
- Reuken PA, Scherag A, Stallmach A. Postcoronavirus Disease Chronic Fatigue Is Frequent
 and Not Only Restricted to Hospitalized Patients. *Critical Care Medicine*. 2021;49(10):e1052.
 - 6. Alkodaymi MS, Omrani OA, Fawzy NA, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: A systematic review and meta-analysis. *Clinical Microbiology and Infection*. 2022;
- Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of
 COVID-19: a systematic review and meta-analysis. *Scientific Reports*. 2021/08/09 2021;11(1):16144.
 doi:10.1038/s41598-021-95565-8

8. Sivan M, Taylor S. NICE guideline on long covid. *BMJ*. 2020;371:m4938. doi:10.1136/bmj.m4938

Stallmach A, Kesselmeier M, Bauer M, et al. Comparison of fatigue, cognitive dysfunction
 and psychological disorders in post-COVID patients and patients after sepsis: is there a specific constellation? *Infection*. 2022/01/07 2022;doi:10.1007/s15010-021-01733-3

 Hartung TJ, Neumann C, Bahmer T, et al. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. *EClinicalMedicine*. 2022;53:101651.

Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international
 cohort: 7 months of symptoms and their impact. *eClinicalMedicine*.
 2021;38doi:10.1016/j.eclinm.2021.101019

12. Bungenberg J, Humkamp K, Hohenfeld C, et al. Long COVID-19: Objectifying most selfreported neurological symptoms. *Annals of Clinical and Translational Neurology*. 2022;9(2):141-154. doi:https://doi.org/10.1002/acn3.51496

García-Sánchez C, Calabria M, Grunden N, et al. Neuropsychological deficits in patients with cognitive complaints after COVID-19. *Brain and Behavior*. 2022;12(3):e2508. doi:https://doi.org/10.1002/brb3.2508

14. Hampshire A, Trender W, Chamberlain SR, et al. Cognitive deficits in people who have recovered from COVID-19. *EClinicalMedicine*. 2021;39:101044.

365 15. Miskowiak K, Johnsen S, Sattler S, et al. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. *European Neuropsychopharmacology*. 2021;46:39-48.

16. Bertuccelli M, Ciringione L, Rubega M, Bisiacchi P, Masiero S, Del Felice A. Cognitive impairment in people with previous COVID-19 infection: A scoping review. *cortex*. 2022;

370 17. Demeyere N, Haupt M, Webb SS, et al. Introducing the tablet-based Oxford Cognitive Screen Plus (OCS-Plus) as an assessment tool for subtle cognitive impairments. *Scientific reports*.
 2021;11(1):1-14.

18. Humphreys GW, Duta MD, Montana L, et al. Cognitive Function in Low-Income and Low-Literacy Settings: Validation of the Tablet-Based Oxford Cognitive Screen in the Health and Aging in

375 Africa: A Longitudinal Study of an INDEPTH Community in South Africa (HAALSI). *The Journals of Gerontology: Series B*. 2016;72(1):38-50. doi:10.1093/geronb/gbw139

Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *Journal of General Internal Medicine*.
 2001/09/01 2001;16(9):606-613. doi:10.1046/j.1525-1497.2001.016009606.x

20. de Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: The
380 Fatigue Assessment Scale (FAS). *British Journal of Health Psychology*. 2004;9(3):279-291. doi:https://doi.org/10.1348/1359107041557048

Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer
patients. *Cancer*. 1999;85(5):1186-1196. doi:https://doi.org/10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N

385 22. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2022. https://www.R-project.org/

23. Cohen J. Statistical power analysis for the behavioral sciences. 1988. 0805802835.

- 24. Gignac GE, Szodorai ET. Effect size guidelines for individual differences researchers. *Personality and individual differences*. 2016;102:74-78.
- Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. *Nature*. 2022/04/01 2022;604(7907):697-707. doi:10.1038/s41586-022-04569-5
 - 26. Squire LR, Zola-Morgan S. The medial temporal lobe memory system. *Science*. 1991;253(5026):1380-1386.
- 395 27. Ceban F, Ling S, Lui LM, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. *Brain, behavior, and immunity*. 2022;101:93-135.

28. Bopp KL, Verhaeghen P. Aging and verbal memory span: A meta-analysis. *The Journals of Gerontology Series B: Psychological Sciences and Social Sciences*. 2005;60(5):P223-P233.

29. Boksem MA, Meijman TF, Lorist MM. Effects of mental fatigue on attention: an ERP study.

400 *Cognitive brain research*. 2005;25(1):107-116.

30. Sturm W, Willmes K. On the functional neuroanatomy of intrinsic and phasic alertness. *Neuroimage*. 2001;14(1):S76-S84.

31. Sara SJ, Bouret S. Orienting and reorienting: the locus coeruleus mediates cognition through arousal. *Neuron*. 2012;76(1):130-141.

405 Figures

Figure 1: Performance on the OCS-Plus domain scales by controls and patients

Note. Distribution of scores on the OCS-Plus domain scales of Delayed Memory, Attention, and Executive Functioning, per group. Grey dots represent individual participants, white squares represent group mean, and dashed lines represent cut-off (1.5 standard deviations below control mean).

410

Figure 2: Distributions of controls and patients scoring below cut-off on OCS-Plus domain scores

Note. Panel A) Percentage of participants under the cut-off (1.5 standard deviations below control mean) per group in the domain scores of interest. Panel B) Percentage of participants per group, who fall under the cut-off in no, one, two, or at least three domain scores.

415